Spark Therapeutics (NASDAQ:ONCE) Stock Rating Reaffirmed by Raymond James Financial

Spark Therapeutics (NASDAQ:ONCE)‘s stock had its “buy” rating restated by research analysts at Raymond James Financial in a research report issued to clients and investors on Tuesday, December 19th.

ONCE has been the topic of several other research reports. Jefferies Group restated a “buy” rating and set a $95.00 price objective on shares of Spark Therapeutics in a report on Tuesday, October 10th. SunTrust Banks set a $101.00 price objective on Spark Therapeutics and gave the stock a “buy” rating in a report on Monday, October 16th. BMO Capital Markets restated a “buy” rating and set a $101.00 price objective on shares of Spark Therapeutics in a report on Wednesday, November 15th. Cowen restated a “buy” rating and set a $95.00 price objective on shares of Spark Therapeutics in a report on Tuesday, October 10th. Finally, Royal Bank of Canada cut their price objective on Spark Therapeutics from $100.00 to $98.00 and set an “outperform” rating on the stock in a report on Wednesday, November 8th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and fifteen have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $76.03.

Shares of Spark Therapeutics (NASDAQ ONCE) traded up $1.21 during trading on Tuesday, reaching $54.07. 557,564 shares of the company’s stock traded hands, compared to its average volume of 1,550,000. Spark Therapeutics has a 12-month low of $41.06 and a 12-month high of $91.75. The company has a market capitalization of $2,000.00 and a PE ratio of -7.51.

Spark Therapeutics (NASDAQ:ONCE) last posted its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($1.90) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.79) by ($0.11). The company had revenue of $1.90 million for the quarter, compared to analyst estimates of $1.40 million. Spark Therapeutics had a negative return on equity of 60.01% and a negative net margin of 1,090.11%. Spark Therapeutics’s quarterly revenue was up 45.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.07) EPS. equities analysts anticipate that Spark Therapeutics will post -7.55 EPS for the current fiscal year.

In other Spark Therapeutics news, insider Katherine A. High sold 5,000 shares of Spark Therapeutics stock in a transaction dated Tuesday, October 31st. The stock was sold at an average price of $83.30, for a total transaction of $416,500.00. Following the transaction, the insider now owns 215,000 shares of the company’s stock, valued at approximately $17,909,500. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Jeffrey D. Marrazzo sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $71.54, for a total value of $1,430,800.00. Following the completion of the sale, the chief executive officer now directly owns 250,000 shares of the company’s stock, valued at approximately $17,885,000. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 62,309 shares of company stock worth $4,621,085. Company insiders own 7.30% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. grew its stake in shares of Spark Therapeutics by 11.6% in the 2nd quarter. BlackRock Inc. now owns 2,053,734 shares of the biotechnology company’s stock valued at $122,689,000 after buying an additional 213,520 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Spark Therapeutics by 5.3% in the 2nd quarter. Vanguard Group Inc. now owns 1,924,463 shares of the biotechnology company’s stock valued at $114,968,000 after buying an additional 96,803 shares in the last quarter. JPMorgan Chase & Co. grew its stake in shares of Spark Therapeutics by 15.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,848,988 shares of the biotechnology company’s stock valued at $164,986,000 after buying an additional 241,016 shares in the last quarter. Janus Henderson Group PLC grew its stake in shares of Spark Therapeutics by 46.4% in the 3rd quarter. Janus Henderson Group PLC now owns 756,088 shares of the biotechnology company’s stock valued at $67,413,000 after buying an additional 239,723 shares in the last quarter. Finally, Orbimed Advisors LLC bought a new stake in shares of Spark Therapeutics in the 3rd quarter valued at approximately $38,340,000. 94.91% of the stock is owned by institutional investors and hedge funds.

WARNING: This article was first posted by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at https://stocknewstimes.com/2018/01/11/spark-therapeutics-once-buy-rating-reaffirmed-at-raymond-james-financial.html.

About Spark Therapeutics

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply